Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126130291 | 12613029 | 1 | I | 20160720 | 20160802 | 20160802 | EXP | US-CIPLA LTD.-2016US10122 | CIPLA | 0.00 | Y | 0.00000 | 20160802 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126130291 | 12613029 | 1 | PS | Irinotecan | IRINOTECAN | 1 | Unknown | 65 MG/M2, ON WEEKS 1, 2, 4, AND 5 | 77219 | 65 | MG/M**2 | ||||||||
| 126130291 | 12613029 | 2 | SS | CELECOXIB. | CELECOXIB | 1 | Oral | 400 MG, BID STARTED 3 DAYS BEFORE SURGERY | 0 | 400 | MG | BID | |||||||
| 126130291 | 12613029 | 3 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | 30 MG/M2, ON WEEKS 1, 2, 4, AND 5 | 0 | 30 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126130291 | 12613029 | 1 | Oesophageal carcinoma |
| 126130291 | 12613029 | 2 | Oesophageal carcinoma |
| 126130291 | 12613029 | 3 | Oesophageal carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126130291 | 12613029 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126130291 | 12613029 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |